Business Description
Abbott Laboratories
NAICS : 339112
SIC : 3841
ISIN : US0028241000
Compare
Compare
Traded in other countries / regions
ABT.USA0Q15.UKABT.MexicoABTT34.BrazilABL.GermanyABT.ArgentinaABT.SwitzerlandABT.AustriaABT.ChileABT_KZ.Kazakhstan IPO Date
1949-04-19Description
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.48 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.45 | |||||
| Debt-to-EBITDA | 1.67 | |||||
| Interest Coverage | 10.09 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.51 | |||||
| Beneish M-Score | -2.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.4 | |||||
| 3-Year EBITDA Growth Rate | 16.4 | |||||
| 3-Year EPS without NRI Growth Rate | 23.8 | |||||
| 3-Year FCF Growth Rate | 20.5 | |||||
| 3-Year Book Growth Rate | 6.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 0.58 | |||||
| Future 3-5Y Total Revenue Growth Rate | 0.55 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.48 | |||||
| 9-Day RSI | 34.23 | |||||
| 14-Day RSI | 34.11 | |||||
| 6-1 Month Momentum % | 5.32 | |||||
| 12-1 Month Momentum % | 5.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.64 | |||||
| Quick Ratio | 1.16 | |||||
| Cash Ratio | 0.57 | |||||
| Days Inventory | 126.89 | |||||
| Days Sales Outstanding | 58.1 | |||||
| Days Payable | 87.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.07 | |||||
| Dividend Payout Ratio | 0.67 | |||||
| 3-Year Dividend Growth Rate | 13.7 | |||||
| Forward Dividend Yield % | 2.11 | |||||
| 5-Year Yield-on-Cost % | 3.81 | |||||
| 3-Year Average Share Buyback Ratio | 0.5 | |||||
| Shareholder Yield % | 3.15 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.16 | |||||
| Operating Margin % | 15.23 | |||||
| Net Margin % | 12.83 | |||||
| ROE % | 14.1 | |||||
| ROA % | 7 | |||||
| ROIC % | 9.69 | |||||
| ROC (Joel Greenblatt) % | 72.4 | |||||
| ROCE % | 11.53 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.05 | |||||
| Forward PE Ratio | 20.96 | |||||
| PE Ratio without NRI | 33.05 | |||||
| Shiller PE Ratio | 38 | |||||
| Price-to-Owner-Earnings | 25.4 | |||||
| PEG Ratio | 2.09 | |||||
| PS Ratio | 4.22 | |||||
| PB Ratio | 4.52 | |||||
| Price-to-Tangible-Book | 41.21 | |||||
| Price-to-Free-Cash-Flow | 31 | |||||
| Price-to-Operating-Cash-Flow | 22.83 | |||||
| EV-to-EBIT | 25.68 | |||||
| EV-to-Forward-EBIT | 18.97 | |||||
| EV-to-EBITDA | 17.48 | |||||
| EV-to-Forward-EBITDA | 16.14 | |||||
| EV-to-Revenue | 4.39 | |||||
| EV-to-Forward-Revenue | 4.24 | |||||
| EV-to-FCF | 32.21 | |||||
| Price-to-Projected-FCF | 1.51 | |||||
| Price-to-DCF (Earnings Based) | 1.06 | |||||
| Price-to-DCF (FCF Based) | 2.18 | |||||
| Price-to-Median-PS-Value | 1.07 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.07 | |||||
| Price-to-Graham-Number | 7.78 | |||||
| Earnings Yield (Greenblatt) % | 3.89 | |||||
| Forward Rate of Return (Yacktman) % | 19.51 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:ABT
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abbott Laboratories Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 40,226 | ||
| EPS (TTM) ($) | 2.93 | ||
| Beta | 0.65 | ||
| Volatility % | 22.08 | ||
| 14-Day RSI | 34.11 | ||
| 14-Day ATR ($) | 1.636786 | ||
| 20-Day SMA ($) | 100.0925 | ||
| 12-1 Month Momentum % | 5.68 | ||
| 52-Week Range ($) | 93.25 - 115.83 | ||
| Shares Outstanding (Mil) | 1,735.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abbott Laboratories Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abbott Laboratories Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Abbott Laboratories Frequently Asked Questions
What is Abbott Laboratories(ABT)'s stock price today?
The current price of ABT is $96.85. The 52 week high of ABT is $115.83 and 52 week low is $93.25.
When is next earnings date of Abbott Laboratories(ABT)?
The next earnings date of Abbott Laboratories(ABT) is 2023-10-18.
Does Abbott Laboratories(ABT) pay dividends? If so, how much?
The Dividend Yield %  of Abbott Laboratories(ABT) is 2.07% (As of Today), Highest Dividend Payout Ratio of Abbott Laboratories(ABT) was 5.3. The lowest was 0.44. And the median was 0.6. The  Forward Dividend Yield % of Abbott Laboratories(ABT) is 2.11%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers